175213-46-4

Basic information

• Product Name: METHYL 1-BOC-4-PIPERIDINEACETATE
• Synonyms: N-BOC-4-PIPERIDINEACETIC ACID METHYL ESTER;METHYL 1-BOC-4-PIPERIDINEACETATE;t-Butyl 4-(2-methoxy-2-oxoethyl)piperidine-1-carboxylate;Methyl N-Boc-4-piperidineacetate Methyl 1-Boc-4-piperidineacetate 4-((Methoxycarbonyl)methyl)piperidine-1-carboxylic acid tert-butyl ester;tert-butyl 4-(2-methoxy-2-oxoethyl)piperidine-1-carboxylate;1-Boc-4-Piperidine acetate methyl ester;1-Boc-4-Piperidine acetic acid methyl ester;Methyl 1-N-Boc-4-piperidineacetate
• CAS NO: 175213-46-4
• Molecular Formula: C₁₃H₂₃NO₄
• Molecular Weight: 257.33
• Product Categories: Amines;blocks;Carboxes;pharmacetical
• Mol File: 175213-46-4.mol
• Article Data: 18

Chemical Properties

• Boiling Point: 323.1 °C at 760 mmHg
• Flash Point: 149.2 °C
• Appearance: /
• Density: 1.062 g/cm³
• Vapor Pressure: 0.000267mmHg at 25°C
• Refractive Index: 1.466
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: -1.88±0.40(Predicted)
• CAS DataBase Reference: METHYL 1-BOC-4-PIPERIDINEACETATE(CAS DataBase Reference)
• NIST Chemistry Reference: METHYL 1-BOC-4-PIPERIDINEACETATE(175213-46-4)
• EPA Substance Registry System: METHYL 1-BOC-4-PIPERIDINEACETATE(175213-46-4)

Safety Data

• Hazardous Substances Data: 175213-46-4(Hazardous Substances Data)

Usage

Chemical Properties

White powder

InChI:InChI=1/C13H23NO4/c1-13(2,3)18-12(16)14-7-5-10(6-8-14)9-11(15)17-4/h10H,5-9H2,1-4H3

Upstream product

• 169206-65-9 1-tert-butoxycarbonyl-4-[(methoxycarbonyl)methylene]piperidine 
• 79099-07-3 N-tert-butyloxycarbonylpiperidin-4-one 
• 67-56-1 methanol 
• 89151-44-0 4-(2-hydroxyethyl)piperidine-1-carboxylic acid tert-butyl ester 
• 24424-99-5 di-tert-butyl dicarbonate 
• 168986-49-0 4-piperidine acetic acid methyl ester 
• 81270-37-3 methyl piperidine-4-acetate hydrochloride 
• 865-33-8 potassium methanolate 
• 7440-44-0 pyrographite 
• 7440-05-3 palladium 
• 157688-46-5 2-(1-(tert-butoxycarbonyl)piperidin-4-yl)acetic acid 
• 18107-18-1 diazomethyl-trimethyl-silane 

Downstream Products

• 81270-37-3 methyl piperidine-4-acetate hydrochloride 
• 1352485-19-8 R,S-2-[4-(1H-indol-3-yl)-trans-cyclohexylamino]-2-[1-(trans-3,5-difluorocinnamoyl)piperidin-4-yl]-acetamide 
• 861451-20-9 tert-butyl 4-(1-methoxy-2-methyl-1-oxopropan-2-yl)piperidine-1-carboxylate 
• 881016-89-3 4-(bromo-carboxy-methyl)-piperidine-1-carboxylic acid tert-butyl ester 
• 622-26-4 4-(2-Hydroxyethyl)piperidine 
• 960391-50-8 C₂₆H₃₅F₂N₃O₃ 
• 960391-38-2 methyl [1-({2-tert-butyl-1-[(4,4-difluorocyclohexyl)methyl]-1H-benzimidazol-5-yl}carbonyl)piperidin-4-yl]acetate 
• 423722-27-4 2-(1-(methylsulfonyl)piperidin-4-yl)acetic acid 
• 177948-33-3 tert-butyl 4-(1-amino-2-methoxy-2-oxoethyl)piperidine-1-carboxylate 
• 1352428-65-9 C₃₀H₃₄F₂N₄O₂ 

Relevant articles and documents

INTRANASAL PHARMACEUTICAL COMPOSITIONS OF CGRP INHIBITORS

Provided is pharmaceutical composition for intranasal delivery, wherein the pharmaceutical composition includes a therapeutically active ingredient including a CGRP inhibitor. Also provided is a method for delivering a CGRP inhibitor to a subject, wherein

SUBSTITUTED PYRIDINES AS INHIBITORS OF DNMT1

The invention is directed to substituted pyridine derivatives. Specifically, the invention is directed to compounds according to Formula (Iar): (Iar) wherein Yar, X1ar, X2ar, R1ar, R2ar, R3ar, R4ar and R5ar are as defined herein; or a pharmaceutically acceptable salt or prodrug thereof. The compounds of the invention are selective inhibitors of DNMT1 and can be useful in the treatment of cancer, pre-cancerous syndromes, beta hemoglobinopathy disorders, sickle cell disease, sickle cell anemia, and beta thalassemia, and diseases associated with DNMT1 inhibition. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting DNMT1 activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.

INHIBITORS OF RENAL OUTER MEDULLARY POTASSIUM CHANNEL

Disclosed are compounds of Formula I and the pharmaceutically acceptable salts thereof, which are inhibitors of the ROMK (Kir1.1) channel. The compounds may be used as diuretic and/or natriuretic agents and for the therapy and prophylaxis of medical conditions including cardiovascular diseases such as hypertension, heart failure and chronic kidney disease and conditions associated with excessive salt and water retention.